Genetic Technologies (ASX:GTG) Total Receivables: A$2.13 Mil (As of Jun. 2024)


What is Genetic Technologies Total Receivables?

Genetic Technologies ASX:GTG Total Receivables is A$2.13 Mil as of Jun. 2024.

Genetic Technologies's Total Receivables for the quarter that ended in Jun. 2024 was A$2.13 Mil.

Genetic Technologies Total Receivables Related Terms

Genetic Technologies Total Receivables Historical Data

* Premium members only.

The historical data trend for Genetic Technologies's Total Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Genetic Technologies Total Receivables Chart

Genetic Technologies Annual Data
Trend Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
Total Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.79 1.07 2.42 1.92 2.13

Genetic Technologies Quarterly Data
Jun19 Dec19 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Total Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 1.12 0.00 2.13 0.00

Genetic Technologies Total Receivables Calculation

Total Receivables is the sum of all receivables owed by customers and affiliates within one year, including:
Accounts Receivable
Notes Receivable
Loans Receivable
Other Current Receivables

Frequently Asked Questions Learn more about Total Receivables →
What does a Total Receivables of A$2.13 Mil mean?
Genetic Technologies (ASX:GTG) has a Total Receivables of A$2.13 Mil as of Jun. 2024. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on Genetic Technologies and its competitors.
Is Genetic Technologies' Total Receivables too high?
Genetic Technologies' current Total Receivables is A$2.13 Mil.
How does Genetic Technologies' Total Receivables compare to LDDD and NOTV?
Genetic Technologies' Total Receivables of A$2.13 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Receivables for a Medical Diagnostics & Research company?
A good Total Receivables depends on the Medical Diagnostics & Research industry context. However, Total Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Receivables mean?
A high Total Receivables can signal that a stock is expensive relative to its fundamentals. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on Genetic Technologies and its competitors. Genetic Technologies's current Total Receivables is A$2.13 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genetic Technologies stock overvalued right now?
Genetic Technologies (ASX:GTG) has a current Total Receivables of A$2.13 Mil. The current Total Receivables is A$2.13 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Receivables calculated?
Total Receivables is calculated from a company's financial statements. For Genetic Technologies (ASX:GTG), the current Total Receivables is A$2.13 Mil as of Jun. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Genetic Technologies Business Description

Address 60-66 Hanover Street, Fitzroy, Melbourne, VIC, AUS, 3065
Genetic Technologies Ltd is an Australia-based molecular diagnostics company that offers predictive testing and assessment tools to help physicians proactively manage women's health. The company has developed BREVAGenplus which is a clinically validated risk assessment test for non-hereditary breast cancer. It also provides genetic testing services including medical testing, animal testing, forensic testing, and plant testing. The company markets BREVAGenplus to healthcare professionals in breast healthcare and imaging centers, as well as to obstetricians/ gynecologists (OBGYNs) and breast cancer risk assessment specialists. The majority of the company's revenue is generated from Australia and the United States. The group has two operating segments: EasyDNA and GeneType/Corporate.